INTRODUCTION:
There is highly prevalence of insulin resistance with hypertension, which is a major risk factor to develop type 2 diabetes mellitus 1 . Because hypertension and diabetes mellitus act as two big risk factors for cardiovascular disease, the risk gives a boost to increase when both synchronizes generally as part of metabolic syndrome. Data from trials of antihypertensive therapy commend that the risk of death, heart disease or stroke is around doubled in hypertensive diabetic patients with compared to those without hypertension 2 .
Most of the classes of antihypertensive drugs contrast with respect to their metabolic effects. For example, nonselective or β1-selective β-blockers drift to reduce insulin sensitivity, while angiotensin receptor-1blockers (ARBs) are tend to have beneficial effects on glycemic control. β-blockers have been revealed to potential appearance of new-onset type-2 DM in patients with hypertension 3 . Cessation of rennin angiotensin system, on other way , have been found to provide metabolic benefits by decreasing oxidative stress and recovering nitric oxide production, which may improve insulin sensitivity in patient with hypertension 4 .
It has been found in many trials that the incidence of new onset diabetes is incomparably deflate in patients treated with ARBs, ACE inhibitors 5 .
In Indian population, there is no widely known studies on correlation between beta blockers and ARBs on blood glucose level. Therefore, the present study was planned to study the comparative effect of beta blockers and ARBs on blood glucose level among Indian population in South Delhi hospital. 
STUDY DESIGN AND METHODOLOGY

ABSTRACT:
Objective: There is highly co-incidence between hypertension and insulin resistance which is the important causative factor to develop diabetes mellitus (DM). There is paucity of data to establish the effect of beta-blockers and ARB on blood glucose level in Indian population. Therefore the present study was planned to search so that confederation among Indian population in a teaching hospital.
Methods:
The research study was carried out in 85 hypertensive patients without diabetes visiting the OPD of University teaching hospital (Majeedia hospital) New Delhi. Blood glucose levels and drug history of hypertensive patients were observed during four month of study.
Results: The gender distribution of hypertensive patients reveals a higher percentage of incidences in males (53%) as compared to females (47%). Hypertensive patient without diabetes mellitus (DM) on beta blockers shows higher incidence of impaired glucose tolerancse (IGT) (13.3%) and DM (5%) as compared to patient receiving ARBs as antihypertensive therapy. There was proportionate increase in incidence as the duration of therapy. None of the patients who were on angiotensin receptor blockers (ARBs) reported any incidence of IGT or DM. Conclusion: Beta blockers may be the risk factor to develop diabetes mellitus type 2 on long term use as an antihypertensive therapy. There was no any incidence of impaired glucose tolerance or diabetes mellitus found in case of patients taking ARBs as an antihypertensive therapy so it can be safely prescribe in hypertensive patients associated with diabetes mellitus type 2. Key Words: Hypertension, Diabetes mellitus, impaired glucose tolerance, Beta blockers and ARBs. 2.5 Sample Collection: Blood samples of hypertensive patients for oral glucose tolerance test were collected by laboratory technician. The collected samples were sent to the in-house pathology lab and the reports were collected and interpreted by the investigators/clinician According to WHO 1999, fasting blood glucose level between 110 to 125 mg/dl and 2 hr blood glucose level, after giving 75 gm glucose through oral route in between 140-200 mg/dl were considered as impaired glucose tolerance. The patients were aforethought diabetic when the fasting blood glucose level was found to be more than 125 mg/dl and 2 hr post prandial blood glucose was more than 200 mg/dl.
2.6 Ethical Considerations: the study was based on the basic principles defined in US 21 CFR part 312.20 and ICH (09 May 1997) 'Guidance for Good Clinical Practice' and the principles enunciated in the Declaration of Helsinki (Edinburgh, October2000). The Protocol and the corresponding Informed Consent Form (ICF) were submitted to the Jamia Hamdard Institutional Review Board (IRB) for the approval of conduct of this study.
OBSERVATION AND RESULT
3.1 Gender assessment of subjects: 85 Patients were assessed to receive antihypertensive therapy during four month of study at Majeedia Hospital. Out of 85 patients 53 % were male and 47% were female ( Table 1 ). 3 .3 Out of 85 hypertensive patients, 45 were prescribed beta blockers. Among beta blockers, atenolol was the most widely prescribed drug followed by metoporolol and carvedilol respectively. 40 patients were prescribed ARBs. Telmisartan is the most widely prescribed drug followed by Losartan Angiotensin receptor blockers (ARB).
Blood glucose levels of patients receiving beta blockers and ARBs:
Blood glucose level of patients taking beta blockers and ARB as antihypertensive therapy was observed during each month. It was found that beta blockers produce impairment in postprandial glycemic control in time dependent manner. It was found that disturbance in blood glucose level increase on prolong therapy of beta blockers. There was no any disturbance of blood glucose level was found as in case of ARB therapy. It was observed that beta blockers cause significant disturbance on blood glucose level as compare with ARBs (Table 3 ).
Total incidence of impaired glucose tolerance (IGT) or diabetes mellitus (DM)
During four month of study it was found that 13.3% incidence of impaired glucose tolerance and 5 % incidence of diabetes mellitus was found in the group of patients who were using beta blockers as antihypertensive therapy. There was no any case of impaired glucose tolerance and Diabetes was found in group of patients who were using ARB as antihypertensive therapy (Table  4 ). 6 . Therefore it is big issue to monitor the metabolic consequences of antihypertensive drug so that potential adverse effect could be minimized. There is no such published study available to establish the relationship between beta blockers and ARBs on blood glucose level in hypertensive patients in Indian population.
The present study compares the effect of beta blockers and ARBs on blood glucose levels of Indian patients receiving antihypertensive therapy. The study was carried out in University Majeedia hospital at New Delhi. The observation was assessed on 85 patients during period of four months.
A higher percentage of male (53) as compared to (47) females was found on gender distribution of hypertensive patients. Patients who were prescribed beta blockes and ARBs In this study hypertensive patients were divided into two groups: those who were taking beta blocker and in other group who were using ARBs as antihypertensive therapy. Higher incidence of impaired glucose tolerance (13.3%) and diabetes mellitus (5%) was found in group of patients who were taking beta blockers as antihypertensive therapy. Thus the high blood glucose levels is a risk factor for onset of diabetes mellitus type 2 and it should be monitored properly when a patients is prescribing beta blockers.
No any incidence of impaired glucose tolerance or diabetes mellitus was observed in group of patients who were taking ARBs as antihypertensive therapy.Most of the literature supports this observation including the HOPE (Heart Outcomes Prevention Evaluation) trial, which indicate a reduced rate of new onset of diabetes mellitus in patients taking ARBs [7] [8] . Angiotensin receptor blockers may exert wholesome effects on glycemic control through a variety of mechanisms related to the inhibition of angiotensin II [9] [10] . ARBs drug has been reported to activate insulin sensitizing peroxisome proliferator-activated receptor, gamma isotype pathways so it shows beneficial effect in glycemic control 11 .
In conclusion, beta blockers worsen the glycemic condition and may increase blood glucose level. It may be the risk factor to develop diabetes mellitus type 2 on long term use as an antihypertensive therapy. There was no any incidence of impaired glucose tolerance or diabetes mellitus found in case of patients taking ARBs as an antihypertensive therapy so it can be safely prescribe in hypertensive patients associated with diabetes mellitus type 2.
